Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
Background The results reported in the TOPAZ-1 phase III trial led to the approval of the combination of cisplatin and gemcitabine with durvalumab as the new first-line standard of care for patients with locally advanced or metastatic cholangiocarcinoma. Objective We performed a clustering analysis to classify patients into different groups based on their mutation profile, correlating the results of the analysis with clinical outcomes. Methods We selected 51 patients with cholangiocarcinoma who were treated with the combination of chemotherapy and durvalumab and who were screened using the next-generation sequencing-based FoundationOne gene panel. We conducted mutation-based clustering of tumors and a survival analysis. Results Three main clusters were identified. Cluster 1 is mostly characterized by mutations in genes belonging to the chromatin modification pathway, altered in 100% of patients. Cluster 2 is characterized by the alteration of several pathways, among which DNA damage control, chromatin modification, RTK/RAS, cell-cycle apoptosis, TP53, and PI3K were the most affected. Finally, most altered pathways in cluster 3 were RTK/RAS and cell-cycle apoptosis. Overall response rate was 4/13 (31%), 12/24 (50%), and 0/10 (0%) in cluster 1, cluster 2, and cluster 3, respectively, and the difference between the three clusters was statistically significant (p = 0.0188). Conclusions By grouping patients into three clusters with distinct molecular and genomic alterations, our analysis showed that patients included in cluster 2 had higher overall response rates, whereas patients included in cluster 3 had no objective response. Further investigations on larger and external cohorts are needed in order to validate our results..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Targeted oncology - 19(2024), 2 vom: 12. Feb., Seite 223-235 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rimini, Margherita [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11523-024-01032-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055290604 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055290604 | ||
| 003 | DE-627 | ||
| 005 | 20240327064913.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11523-024-01032-5 |2 doi | |
| 035 | |a (DE-627)SPR055290604 | ||
| 035 | |a (SPR)s11523-024-01032-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.81 |2 bkl | ||
| 100 | 1 | |a Rimini, Margherita |e verfasserin |0 (orcid)0000-0002-4047-2585 |4 aut | |
| 245 | 1 | 0 | |a Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background The results reported in the TOPAZ-1 phase III trial led to the approval of the combination of cisplatin and gemcitabine with durvalumab as the new first-line standard of care for patients with locally advanced or metastatic cholangiocarcinoma. Objective We performed a clustering analysis to classify patients into different groups based on their mutation profile, correlating the results of the analysis with clinical outcomes. Methods We selected 51 patients with cholangiocarcinoma who were treated with the combination of chemotherapy and durvalumab and who were screened using the next-generation sequencing-based FoundationOne gene panel. We conducted mutation-based clustering of tumors and a survival analysis. Results Three main clusters were identified. Cluster 1 is mostly characterized by mutations in genes belonging to the chromatin modification pathway, altered in 100% of patients. Cluster 2 is characterized by the alteration of several pathways, among which DNA damage control, chromatin modification, RTK/RAS, cell-cycle apoptosis, TP53, and PI3K were the most affected. Finally, most altered pathways in cluster 3 were RTK/RAS and cell-cycle apoptosis. Overall response rate was 4/13 (31%), 12/24 (50%), and 0/10 (0%) in cluster 1, cluster 2, and cluster 3, respectively, and the difference between the three clusters was statistically significant (p = 0.0188). Conclusions By grouping patients into three clusters with distinct molecular and genomic alterations, our analysis showed that patients included in cluster 2 had higher overall response rates, whereas patients included in cluster 3 had no objective response. Further investigations on larger and external cohorts are needed in order to validate our results. | ||
| 700 | 1 | |a Loi, Eleonora |4 aut | |
| 700 | 1 | |a Rizzato, Mario Domenico |4 aut | |
| 700 | 1 | |a Pressiani, Tiziana |4 aut | |
| 700 | 1 | |a Vivaldi, Caterina |4 aut | |
| 700 | 1 | |a Gusmaroli, Eleonora |4 aut | |
| 700 | 1 | |a Antonuzzo, Lorenzo |4 aut | |
| 700 | 1 | |a Martinelli, Erika |4 aut | |
| 700 | 1 | |a Garajova, Ingrid |4 aut | |
| 700 | 1 | |a Giordano, Guido |4 aut | |
| 700 | 1 | |a Lucchetti, Jessica |4 aut | |
| 700 | 1 | |a Schirripa, Marta |4 aut | |
| 700 | 1 | |a Cornara, Noemi |4 aut | |
| 700 | 1 | |a Rossari, Federico |4 aut | |
| 700 | 1 | |a Vitiello, Francesco |4 aut | |
| 700 | 1 | |a Amadeo, Elisabeth |4 aut | |
| 700 | 1 | |a Persano, Mara |4 aut | |
| 700 | 1 | |a Piva, Vittoria Matilde |4 aut | |
| 700 | 1 | |a Balsano, Rita |4 aut | |
| 700 | 1 | |a Salani, Francesca |4 aut | |
| 700 | 1 | |a Pircher, Chiara |4 aut | |
| 700 | 1 | |a Cascinu, Stefano |4 aut | |
| 700 | 1 | |a Niger, Monica |4 aut | |
| 700 | 1 | |a Fornaro, Lorenzo |4 aut | |
| 700 | 1 | |a Rimassa, Lorenza |4 aut | |
| 700 | 1 | |a Lonardi, Sara |4 aut | |
| 700 | 1 | |a Scartozzi, Mario |4 aut | |
| 700 | 1 | |a Zavattari, Patrizia |4 aut | |
| 700 | 1 | |a Casadei-Gardini, Andrea |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Targeted oncology |d Springer International Publishing, 2006 |g 19(2024), 2 vom: 12. Feb., Seite 223-235 |w (DE-627)SPR020528167 |w (DE-600)2222136-0 |x 1776-260X |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g number:2 |g day:12 |g month:02 |g pages:223-235 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11523-024-01032-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.81 |q VZ |
| 951 | |a AR | ||
| 952 | |d 19 |j 2024 |e 2 |b 12 |c 02 |h 223-235 | ||